MD MAS - Axonics Chief Officer

0I3 Stock  EUR 63.50  0.00  0.00%   

Insider

MD MAS is Chief Officer of Axonics
Age 59
Phone949 396 6322
Webhttps://www.axonics.com

Axonics Management Efficiency

The company has return on total asset (ROA) of (0.0624) % which means that it has lost $0.0624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1453) %, meaning that it generated substantial loss on money invested by shareholders. Axonics' management efficiency ratios could be used to measure how well Axonics manages its routine affairs as well as how well it operates its assets and liabilities.
Axonics has accumulated 10.01 M in total debt with debt to equity ratio (D/E) of 0.02, which may suggest the company is not taking enough advantage from borrowing. Axonics has a current ratio of 13.35, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Axonics until it has trouble settling it off, either with new capital or with free cash flow. So, Axonics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Axonics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Axonics to invest in growth at high rates of return. When we think about Axonics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 9 records

INSIDER Age

Caroline GlynnBJs Wholesale Club
55
Robert EddyBJs Wholesale Club
50
Brian PoulliotBJs Wholesale Club
48
Catherine ParkBJs Wholesale Club
N/A
Jeff DesrochesBJs Wholesale Club
45
CGMA CPABJs Wholesale Club
41
William WernerBJs Wholesale Club
45
Graham LuceBJs Wholesale Club
53
Paul CichockiBJs Wholesale Club
53
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation systems. Axonics, Inc. was incorporated in 2012 and is headquartered in Irvine, California. AXONICS INC operates under Medical Devices classification in Germany and is traded on Frankfurt Stock Exchange. It employs 416 people. Axonics (0I3) is traded on Frankfurt Exchange in Germany and employs 517 people.

Management Performance

Axonics Leadership Team

Elected by the shareholders, the Axonics' board of directors comprises two types of representatives: Axonics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axonics. The board's role is to monitor Axonics' management team and ensure that shareholders' interests are well served. Axonics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axonics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Erik Amble, Independent Director
Jane Kiernan, Independent Director
MD MAS, Chief Officer
Raymond Cohen, Chief Executive Officer, Director
Karen Noblett, Chief Medical Officer
JD Esq, Gen VP
John Woock, Chief Marketing Officer
Neil Bhalodkar, VP Relations
Nancy Snyderman, Independent Director
Robert McNamara, Independent Director
Alfred Ford, Chief Commercial Officer
Michael Carrel, Independent Chairman of the Board
Dan Dearen, President, Chief Financial Officer
Danny Dearen, Pres CFO
Rinda Sama, Chief Operating Officer
Juliet Bakker, Independent Director
Aaron Pettit, G Officer
David Demski, Director
Prabodh Mathur, Chief Product Development Officer
Guangqiang Jiang, Chief Technology Officer

Axonics Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axonics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in Axonics Stock

Axonics financial ratios help investors to determine whether Axonics Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axonics with respect to the benefits of owning Axonics security.